Expert Interview
Discussing the Long-term Open Label Extension Study of Larimar's Nomlabofusp for Friedreich’s Ataxia
Ticker(s): LRMR, BIIB, RETAInstitution: UCLA
- Clinical Professor of Neurology. Director of Ataxia Clinic and Neurogenetics Clinical Trials at UCLA Medical Center.
- Over 30 years of experience diagnosing and treating Friedreich's Ataxia; has served on the National Ataxia Foundation's (NAF) Medical Research Advisory Board, NAF’s Board of Directors and is NAF’s Medical Director.
- Helped develop the National Ataxia Database for clinical research and has participated in 2 natural history studies (for dominant Ataxia and Friedreich’s Ataxia) in addition to numerous clinical drug trials.
Roughly how many patients with friedreich's ataxia do you currently manage?
Added By: ben_adminOn a scale from 1-10, 10 being extremely exciting, where would you rate your level of excitement for Nomlabofusp?
Added By: ben_adminHow do you compare Nomlabofusp to the current standard of care for FA?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
